Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Medical System Holdings's earnings before interest and taxes (EBIT) for the
six
months ended in Dec. 2025 was €117.4 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €256.9 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
China Medical System Holdings's annualizedROC % for the quarter that ended in Dec. 2025 was 6.92%.
China Medical System Holdings's annualizedROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 80.34%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
China Medical System Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 9.78%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Medical System Holdings EBIT Related Terms
China Medical System Holdings EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, China Medical System Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Medical System Holdings EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Medical System Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where China Medical System Holdings's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €256.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Medical System Holdings (STU:2M7C) has a EBIT of €256.9 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on China Medical System Holdings.
Is China Medical System Holdings' EBIT too high?
China Medical System Holdings' current EBIT is €256.9 Mil. Overall, China Medical System Holdings has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does China Medical System Holdings' EBIT compare to ZTS?
China Medical System Holdings' EBIT of €256.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on China Medical System Holdings. China Medical System Holdings's current EBIT is €256.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Medical System Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Medical System Holdings (STU:2M7C) is currently considered Fairly Valued. The stock's GF Value™ is €1.36, compared to a current price of €1.32 — trading 2.9% below its estimated fair value. The current EBIT is €256.9 Mil. China Medical System Holdings' overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For China Medical System Holdings (STU:2M7C), the current EBIT is €256.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Medical System Holdings (STU:2M7C) Overvalued in 2026?
Based on GuruFocus' analysis, China Medical System Holdings stock appears to be undervalued.
The current stock price of €1.32 is trading 2.9% below its estimated GF Value™ of €1.36.
GuruFocus considers China Medical System Holdings to be Fairly Valued.
Key valuation signals for STU:2M7C:
EBIT: €256.9 Mil
GF Value™: €1.36 vs. price of €1.32 (2.9% below fair value)
No single metric tells the full story. See the STU:2M7C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Medical System Holdings Ltd is a holding company. Along with its subsidiaries, it is engaged in the research and development, production, promotion and sale of medicines. The company's reportable segments are: (i) Integrated pharmaceuticals portfolio and (ii) Skin diseases related business. The majority of the company's revenue, which consists of pharmaceutical products sales, is derived from the integrated pharmaceuticals portfolio segment.
76GF Score
Get the complete analysis for STU:2M7C
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2M7C has been successfully added to your 
